Cohance Lifesciences Limited
COHANCE.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$170.47B
Close$
$487.22
9.3% upside
Current Fair Value
9.3% upsideUndervalued by 9.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $170.47 Billion |
|---|---|
| Enterprise Value | $170.47 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.69 |
| Beta | 0.62 |
| Outstanding Shares | 382,567,140 |
Return
| Return on Equity | 13.73% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 104.5 |
|---|---|
| PEG | -534.11 |
| Price to Sales | 11.43 |
| Price to Book Ratio | 9.28 |
| Enterprise Value to Revenue | 11.24 |
| Enterprise Value to EBIT | 50.37 |
| Enterprise Value to Net Income | 67 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
$4.38 B
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$4.80 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cohance Lifesciences Limited
2,576 employees
CEO: Umang Vohra Headquartered in Hyderabad, Cohance Lifesciences Limited is a pharmaceutical company with a core focus on providing contract development and manufacturing (CDMO) services, developing active pharmaceutical ingredients (APIs), and manufact...